Literature DB >> 12569151

Huntingtin in health and disease.

Anne B Young1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12569151      PMCID： PMC151871          DOI： 10.1172/JCI17742

Source DB:  PubMed          Journal:  J Clin Invest        ISSN： 0021-9738            Impact factor:   14.808


× No keyword cloud information.
  63 in total

1.  The Huntington's disease protein interacts with p53 and CREB-binding protein and represses transcription.

Authors:  J S Steffan; A Kazantsev; O Spasic-Boskovic; M Greenwald; Y Z Zhu; H Gohler; E E Wanker; G P Bates; D E Housman; L M Thompson
Journal:  Proc Natl Acad Sci U S A       Date:  2000-06-06       Impact factor: 11.205

2.  Polyglutamine-expanded huntingtin promotes sensitization of N-methyl-D-aspartate receptors via post-synaptic density 95.

Authors:  Y Sun; A Savanenin; P H Reddy; Y F Liu
Journal:  J Biol Chem       Date:  2001-04-23       Impact factor: 5.157

3.  Insoluble detergent-resistant aggregates form between pathological and nonpathological lengths of polyglutamine in mammalian cells.

Authors:  A Kazantsev; E Preisinger; A Dranovsky; D Goldgaber; D Housman
Journal:  Proc Natl Acad Sci U S A       Date:  1999-09-28       Impact factor: 11.205

4.  Wild-type huntingtin reduces the cellular toxicity of mutant huntingtin in vivo.

Authors:  B R Leavitt; J A Guttman; J G Hodgson; G H Kimel; R Singaraja; A W Vogl; M R Hayden
Journal:  Am J Hum Genet       Date:  2000-12-20       Impact factor: 11.025

5.  Neuroprotective effects of creatine in a transgenic mouse model of Huntington's disease.

Authors:  R J Ferrante; O A Andreassen; B G Jenkins; A Dedeoglu; S Kuemmerle; J K Kubilus; R Kaddurah-Daouk; S M Hersch; M F Beal
Journal:  J Neurosci       Date:  2000-06-15       Impact factor: 6.167

6.  Polyglutamine aggregates alter protein folding homeostasis in Caenorhabditis elegans.

Authors:  S H Satyal; E Schmidt; K Kitagawa; N Sondheimer; S Lindquist; J M Kramer; R I Morimoto
Journal:  Proc Natl Acad Sci U S A       Date:  2000-05-23       Impact factor: 11.205

7.  Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease.

Authors:  M Chen; V O Ona; M Li; R J Ferrante; K B Fink; S Zhu; J Bian; L Guo; L A Farrell; S M Hersch; W Hobbs; J P Vonsattel; J H Cha; R M Friedlander
Journal:  Nat Med       Date:  2000-07       Impact factor: 53.440

8.  Environmental stimulation increases survival in mice transgenic for exon 1 of the Huntington's disease gene.

Authors:  R J Carter; M J Hunt; A J Morton
Journal:  Mov Disord       Date:  2000-09       Impact factor: 10.338

9.  Inactivation of Hdh in the brain and testis results in progressive neurodegeneration and sterility in mice.

Authors:  I Dragatsis; M S Levine; S Zeitlin
Journal:  Nat Genet       Date:  2000-11       Impact factor: 38.330

10.  Loss of huntingtin-mediated BDNF gene transcription in Huntington's disease.

Authors:  C Zuccato; A Ciammola; D Rigamonti; B R Leavitt; D Goffredo; L Conti; M E MacDonald; R M Friedlander; V Silani; M R Hayden; T Timmusk; S Sipione; E Cattaneo
Journal:  Science       Date:  2001-06-14       Impact factor: 47.728
View more
  30 in total

1.  Mutant huntingtin-impaired degradation of beta-catenin causes neurotoxicity in Huntington's disease.

Authors:  Juliette D Godin; Ghislaine Poizat; Miriam A Hickey; Florence Maschat; Sandrine Humbert
Journal:  EMBO J       Date:  2010-06-08       Impact factor: 11.598

Review 2.  Neurodegeneration: what is it and where are we?

Authors:  Serge Przedborski; Miquel Vila; Vernice Jackson-Lewis
Journal:  J Clin Invest       Date:  2003-01       Impact factor: 14.808

Review 3.  Engineered antibody therapies to counteract mutant huntingtin and related toxic intracellular proteins.

Authors:  David C Butler; Julie A McLear; Anne Messer
Journal:  Prog Neurobiol       Date:  2011-11-18       Impact factor: 11.685

4.  What do we tell the children? Contrasting the disclosure choices of two HD families regarding risk status and predictive genetic testing.

Authors:  Kathryn Holt
Journal:  J Genet Couns       Date:  2006-08       Impact factor: 2.537

5.  Clioquinol down-regulates mutant huntingtin expression in vitro and mitigates pathology in a Huntington's disease mouse model.

Authors:  Trent Nguyen; Aaron Hamby; Stephen M Massa
Journal:  Proc Natl Acad Sci U S A       Date:  2005-08-08       Impact factor: 11.205

6.  Cloning, expression, purification, crystallization and preliminary crystallographic analysis of pseudo death-effector domain of HIPPI, a molecular partner of Huntingtin-interacting protein HIP-1.

Authors:  Manisha Banerjee; Pritha Majumder; Nitai P Bhattacharyya; Jiban K Dattagupta; Udayaditya Sen
Journal:  Acta Crystallogr Sect F Struct Biol Cryst Commun       Date:  2006-11-30

Review 7.  Autophagy and neurodegeneration.

Authors:  Annamaria Ventruti; Ana Maria Cuervo
Journal:  Curr Neurol Neurosci Rep       Date:  2007-09       Impact factor: 5.081

Review 8.  Therapeutic gene silencing in neurological disorders, using interfering RNA.

Authors:  G Scott Ralph; Nicholas D Mazarakis; Mimoun Azzouz
Journal:  J Mol Med (Berl)       Date:  2005-03-10       Impact factor: 4.599

9.  Vaccinia-related kinase 2 mediates accumulation of polyglutamine aggregates via negative regulation of the chaperonin TRiC.

Authors:  Sangjune Kim; Do-Young Park; Dohyun Lee; Wanil Kim; Young-Hun Jeong; Juhyun Lee; Sung-Kee Chung; Hyunjung Ha; Bo-Hwa Choi; Kyong-Tai Kim
Journal:  Mol Cell Biol       Date:  2013-12-02       Impact factor: 4.272

10.  The sirtuin 2 inhibitor AK-7 is neuroprotective in Huntington's disease mouse models.

Authors:  Vanita Chopra; Luisa Quinti; Jinho Kim; Lorraine Vollor; K Lakshmi Narayanan; Christina Edgerly; Patricia M Cipicchio; Molly A Lauver; Soo Hyuk Choi; Richard B Silverman; Robert J Ferrante; Steven Hersch; Aleksey G Kazantsev
Journal:  Cell Rep       Date:  2012-11-29       Impact factor: 9.423
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.